Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek Ruchika Sharma26 May 2025 11:37 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has...
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 3:42 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis Ruchika Sharma2 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the U.S. Food ...
